FI944561A0 - HIV neutraliserande monoklonala rekombinanthumanantikroppar för prevention och behandling av HIV-infektion - Google Patents
HIV neutraliserande monoklonala rekombinanthumanantikroppar för prevention och behandling av HIV-infektionInfo
- Publication number
- FI944561A0 FI944561A0 FI944561A FI944561A FI944561A0 FI 944561 A0 FI944561 A0 FI 944561A0 FI 944561 A FI944561 A FI 944561A FI 944561 A FI944561 A FI 944561A FI 944561 A0 FI944561 A0 FI 944561A0
- Authority
- FI
- Finland
- Prior art keywords
- hiv
- prevention
- treatment
- monoclonal antibodies
- recombinant human
- Prior art date
Links
- 208000031886 HIV Infections Diseases 0.000 title 1
- 208000037357 HIV infectious disease Diseases 0.000 title 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86170192A | 1992-04-01 | 1992-04-01 | |
| PCT/US1993/002629 WO1993019785A1 (en) | 1992-04-01 | 1993-03-23 | Recombinant human hiv-neutralizing monoclonal antibodies for prevention and treatment of hiv infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI944561A FI944561A (sv) | 1994-09-30 |
| FI944561A0 true FI944561A0 (sv) | 1994-09-30 |
Family
ID=25336532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI944561A FI944561A0 (sv) | 1992-04-01 | 1994-09-30 | HIV neutraliserande monoklonala rekombinanthumanantikroppar för prevention och behandling av HIV-infektion |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0577243A3 (sv) |
| JP (1) | JPH06217791A (sv) |
| KR (1) | KR950700761A (sv) |
| CN (1) | CN1081716A (sv) |
| AU (2) | AU3928593A (sv) |
| BG (1) | BG99074A (sv) |
| CA (1) | CA2093099A1 (sv) |
| CZ (1) | CZ239694A3 (sv) |
| FI (1) | FI944561A0 (sv) |
| HU (1) | HUT70461A (sv) |
| IL (1) | IL105145A0 (sv) |
| MX (1) | MX9301858A (sv) |
| NO (1) | NO943653L (sv) |
| NZ (1) | NZ251582A (sv) |
| RU (1) | RU94045907A (sv) |
| SK (1) | SK116294A3 (sv) |
| WO (1) | WO1993019785A1 (sv) |
| YU (1) | YU22693A (sv) |
| ZA (1) | ZA932308B (sv) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ511291A (en) * | 1998-10-30 | 2003-08-29 | Novozymes As | A method for selecting a protein variant that has reduced immunogenicity as compared with the parent or wild-type protein |
| US7560529B2 (en) | 2001-04-24 | 2009-07-14 | FDS Pharma | Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence |
| RU2221873C2 (ru) * | 2001-04-24 | 2004-01-20 | Закрытое акционерное общество "АСГЛ-Фармацевтические Инновации" | Способ получения каталитических антител (варианты), антигены для иммунизации и нуклеотидная последовательность |
| FR2844455B1 (fr) * | 2002-09-13 | 2007-12-14 | Lab Francais Du Fractionnement | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
| US8332159B2 (en) | 2003-02-20 | 2012-12-11 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Method for enhancing efficacy of preparation of monoclonal antibody |
| WO2009029569A1 (en) * | 2007-08-24 | 2009-03-05 | Novartis Vaccines And Diagnostics Inc. | Hiv env proteins with modifications in the v3 loop |
| AU2009333559B2 (en) | 2008-12-09 | 2015-03-12 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
| WO2015117008A2 (en) * | 2014-01-31 | 2015-08-06 | The Rockefeller University | Broadly neutralizing anti-hiv antibodies and epitope therefor |
| TWI733652B (zh) * | 2014-07-11 | 2021-07-21 | 美商基利科學股份有限公司 | 用於治療ＨＩＶ之ｔｏｌｌ樣受體調節劑 |
| EP3194401B1 (en) | 2014-09-16 | 2020-10-21 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
| WO2021227138A1 (zh) * | 2020-05-09 | 2021-11-18 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 针对新型冠状病毒的单克隆抗体或其抗原结合部分 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE122237T1 (de) * | 1987-05-29 | 1995-05-15 | Tanox Biosystems Inc | Hiv-1 neutralisierende monoklonale antikörper. |
| EP0311228A3 (en) * | 1987-10-09 | 1990-05-02 | Repligen Corporation | Recombinant polypeptides and their uses, including assay for aids virus |
| CA2058630A1 (en) * | 1989-06-05 | 1990-12-06 | Charles F. Scott, Jr. | Human monoclonal antibodies to hiv-1 mn gp 120 |
| EP0535154A4 (en) * | 1990-06-15 | 1993-12-01 | New York University | Heterohybridomas producing human monoclonal antibodies to hiv-1 |
| CA2128879A1 (en) * | 1992-01-29 | 1993-08-05 | Marie E. Beckner | Aamp-1, a protein with local homologies to hiv-1 env and nef proteins |
-
1993
- 1993-03-23 HU HU9402824A patent/HUT70461A/hu unknown
- 1993-03-23 RU RU94045907/13A patent/RU94045907A/ru unknown
- 1993-03-23 AU AU39285/93A patent/AU3928593A/en not_active Abandoned
- 1993-03-23 CZ CZ942396A patent/CZ239694A3/cs unknown
- 1993-03-23 NZ NZ251582A patent/NZ251582A/en unknown
- 1993-03-23 WO PCT/US1993/002629 patent/WO1993019785A1/en not_active Application Discontinuation
- 1993-03-23 SK SK1162-94A patent/SK116294A3/sk unknown
- 1993-03-24 IL IL105145A patent/IL105145A0/xx unknown
- 1993-03-31 EP EP9393302546A patent/EP0577243A3/en not_active Ceased
- 1993-03-31 CA CA002093099A patent/CA2093099A1/en not_active Abandoned
- 1993-03-31 CN CN93105210A patent/CN1081716A/zh active Pending
- 1993-03-31 MX MX9301858A patent/MX9301858A/es unknown
- 1993-03-31 ZA ZA932308A patent/ZA932308B/xx unknown
- 1993-03-31 AU AU35630/93A patent/AU658987B2/en not_active Ceased
- 1993-04-01 JP JP5098474A patent/JPH06217791A/ja active Pending
- 1993-04-01 YU YU22693A patent/YU22693A/sh unknown
-
1994
- 1994-09-28 BG BG99074A patent/BG99074A/xx unknown
- 1994-09-30 FI FI944561A patent/FI944561A0/sv unknown
- 1994-09-30 NO NO943653A patent/NO943653L/no not_active Application Discontinuation
- 1994-09-30 KR KR1019940703497A patent/KR950700761A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO943653D0 (no) | 1994-09-30 |
| AU3563093A (en) | 1993-10-07 |
| RU94045907A (ru) | 1996-11-10 |
| EP0577243A3 (en) | 1994-11-02 |
| NO943653L (no) | 1994-11-30 |
| SK116294A3 (en) | 1996-11-06 |
| HUT70461A (en) | 1995-10-30 |
| FI944561A (sv) | 1994-09-30 |
| IL105145A0 (en) | 1993-07-08 |
| CA2093099A1 (en) | 1993-10-02 |
| NZ251582A (en) | 1997-07-27 |
| JPH06217791A (ja) | 1994-08-09 |
| AU3928593A (en) | 1993-11-08 |
| YU22693A (sh) | 1997-01-08 |
| WO1993019785A1 (en) | 1993-10-14 |
| KR950700761A (ko) | 1995-02-20 |
| AU658987B2 (en) | 1995-05-04 |
| HU9402824D0 (en) | 1994-11-28 |
| CN1081716A (zh) | 1994-02-09 |
| MX9301858A (es) | 1994-03-31 |
| EP0577243A2 (en) | 1994-01-05 |
| CZ239694A3 (en) | 1995-07-12 |
| BG99074A (en) | 1995-11-30 |
| ZA932308B (en) | 1994-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0831873A4 (en) | COMBINATORY THERAPY FOR THE TREATMENT OF HIV AND OTHER VIRAL INFECTIONS | |
| KR890002547A (ko) | Hiv 감염의 치료 및 진단용 모노클로날항체 및 펩티드 | |
| ZA896864B (en) | Method and composition for the treatment and prevention of viral infections | |
| GB9019812D0 (en) | Novel antibodies for treatment and prevention of infection in animals and man | |
| NO20005839D0 (no) | Preparater for behandling av HIV og andre virale infeksjoner | |
| NO955291D0 (no) | System for viral inaktivering av blod | |
| ZA90245B (en) | Treatment of diseases associated with hiv infections | |
| FI944561A0 (sv) | HIV neutraliserande monoklonala rekombinanthumanantikroppar för prevention och behandling av HIV-infektion | |
| KR950703360A (ko) | 미코박테리아 바케로부터의 치료제 및 hiv감염에 대한 그의 사용(therapeutic agent from mycobacterrium vaccae and its use against hiv infection) | |
| NO940810D0 (no) | Behandling av virusinfeksjoner | |
| EP0339163A3 (en) | Monoclonal antibodies specific for hiv and hybridomas for their production | |
| LV10191A (lv) | Farmaceitiski lidzekli hepatita B virusa izraisito infekciju un slimibu arstesanai | |
| AU591017B2 (en) | Human monoclonal antibody and drug for prophylaxis and treatment of infectious diseases comprising same as effective ingredient | |
| NO965591D0 (no) | Kombinasjonsbehandling av HIV-infeksjon | |
| IL102815A0 (en) | Pharmaceutical compositions and method for the treatment of infection caused by the human immunodeficiency virus | |
| EP0655919A4 (en) | TREATMENT OF VIRAL INFECTIONS IN MAN. | |
| NO960551D0 (no) | Antistoff basert behandling av HIV infeksjon | |
| EE9500019A (et) | Farmatseutiline kompositsioon viirusliku infektsiooni ja neoplasma raviks | |
| LTIP472A (en) | Composition for the treatment of infection and disease caused by hepatit b virus | |
| IE880770L (en) | Treatment of viral infections | |
| DK630089A (da) | Anvendelse af aryloxyalkanoler og estere deraf til fremstilling af farmaceutika til behandling af retrovirusinfektioner | |
| KR900007413A (ko) | 에이즈 발병방지, 치료제 및 그 치료용 조성물 | |
| AU2880495A (en) | Use of pharmaceutical agents for alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses | |
| BR9106503A (pt) | Diagnostico e tratamento de hepatite viral | |
| BG52099B2 (en) | Gel for the treatment of skin viral infections |